Company intelligence / Profile preview

AltheRx Pharmaceuticals

Malvern, Pennsylvania, United States

Ownership: Private
Development stage: Other

Overview

Solabegron, AltheRx’s lead program, demonstrated statistically significant improvements in OAB symptoms versus placebo and favorable safety in Phase 2, with additional Phase 2 data in IBS showing significant reduction in pain; the company planned to advance to Phase 3 for OAB and initiate a Phase 2b study for IBS before clinical/program assets were transferred via merger to Velicept Therapeutics

Therapeutic areas: UrologyGastroenterology
Modalities: Small molecule
Industry: Biotech

Partnerships

None disclosed prior to merger

Beyond the preview

Go deeper on AltheRx Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AltheRx Pharmaceuticals.

Explore the full profile